

Date: April 25, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051
Scrip Symbol: SUVENPHAR

Sub: Press Release – Effective date for Scheme of Amalgamation of Cohance Lifesciences Limited (“Transferor Company”) with and into Suven Pharmaceuticals Limited (“Transferee Company”)

Dear Sir/Madam,

We enclose a copy of the press release in connection with effective date for scheme of Amalgamation of Cohance Lifesciences Limited with and into Suven Pharmaceuticals Limited

We request to take the aforesaid information on your records.

Thanking you.

Yours faithfully,
For **Suven Pharmaceuticals Limited**

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Encl: As above

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236



Suven Pharmaceuticals Announces May 1, 2025 as Effective Date for Amalgamation of Cohance Lifesciences

Mumbai/Hyderabad, April 25, 2025

Suven Pharmaceuticals Limited (BSE: 543064, NSE: SUVENPHAR), a leading contract development and manufacturing organization (CDMO), announced that it has received final approval from the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, Government of India, for foreign investment under applicable regulations. This marks the final regulatory clearance required to implement the Scheme of Amalgamation between Cohance Lifesciences Limited and Suven Pharmaceuticals Limited, a transaction previously approved by shareholders and sanctioned by the Hon'ble NCLT, Mumbai Bench.

In line with the terms of the approved Scheme of Amalgamation, the merger will take effect from the business opening hours of **1st May 2025**, following the satisfaction of all prescribed conditions.

The merged company will operate under the name **Cohance Lifesciences Limited**, subject to applicable regulatory approvals, reflecting a unified platform with expanded CDMO capabilities.

"This approval is a significant milestone and reinforces the strategic vision behind the merger," said Vivek Sharma, Executive Chairman, Suven Pharmaceuticals. "We are combining niche, technology-led capabilities to create a differentiated, innovation-driven global CDMO. This integration positions us to scale complex modalities such as ADCs and Oligonucleotides, deepen customer partnerships, and enhance execution across the value chain—enabling us to deliver on our US\$1 billion(INR85bn) revenue ambition through a mix of organic growth and strategic acquisitions."

The merged entity will operate with an expanded scope of capabilities across the pharmaceutical value chain, combining Suven's scale and commercial execution strengths with Cohance's domain expertise in Antibody-Drug Conjugates (ADCs) and complex chemistry platforms. This integration strengthens our positioning as

an innovation driven integrated CDMO partner to global innovators, with a focus on scaling high-growth modalities such as ADCs and oligonucleotides.

The Board has also approved Thursday, May 8, 2025, as the Record Date for determining the eligible shareholders of Cohance Lifesciences Limited who shall receive equity shares of Suven Pharmaceuticals as per the approved share exchange ratio under the Scheme of Amalgamation.

With the merger becoming effective, the Company has initiated the operational and organizational integration, aligning systems, capabilities, and teams.

-ENDS-

About Suven Pharmaceuticals:

Suven Pharma is a leading technology-driven CDMO, providing integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators. With over 100 active projects and a strong pipeline of late-stage molecules, Suven has built a reputation for delivering complex solutions at a scale with precision. Strengthening its technology expertise through strategic acquisitions—Sapala (June 2024) for oligonucleotides and NJ Bio for ADC technology (December 2024)—the platform (including Cohance lifesciences) has achieved consolidated revenue of US\$318 million (LTM, Dec24) while maintaining industry-leading margins and ROCEs over the past five years.

For more information, please visit www.suvenpharm.com OR contact:

Cyndrella Carvalho, Head – Investor Relations,

Suven Pharmaceutical Ltd

Tel: 040 2354 3311

Email: cyndrella.carvalho@suvenpharm.com

Gavin Desa / Rishab Barar

CDR India

Tel: +91 98206 37649/ +91 77770 35061

Email: gavin@cdr-india.com

rishab@cdr-india.com

Disclaimer. Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.